Douglas Rising
Recursive Pharmaceuticals (RXRX) added ~11% on Wednesday morning, after JP Morgan upgraded the AI-based biotech from neutral to overweight, citing blockbuster selling potential for the company’s lead asset, REC-4881.
Analyst Priyanka Grover argued that REC-4881, for which
